Paolo Pinton Lab__Signal Transduction

 

HomeLab membersResearchLab facilitiesPublicationsSelected PublicationsLab fundsMapContacts & Information

 

CURRICULUM VITAE GIAMPAOLO MORCIANO

 

Date and place of birth: Tricase (LE), 4 April 1987 Nationality: Italian

Affiliation and official address: Dept. of Medical Sciences, University of Ferrara, Paolo Pinton's Lab, c/o CUBO Via Fossato di Mortara 70, 44121 Ferrara, Italy.

Telephone: +39 0532 455804

e-mail: mrcgpl@unife.it

 

EDUCATION
2010: BS degree in Biological Sciences, three years (University of Ferrara)
2012: MS degree in Biomolecular & Cellular Sciences, two years, summa cum laude (University of Ferrara)
2016: PhD in Biochemistry, Molecular Biology and Biotechnology (University of Ferrara)
2019: License to the profession of biologist
2020: Cultore della Materia s.c. 06/A2 - PATOLOGIA GENERALE E PATOLOGIA CLINICA, s.s. MED/04


CAREER/EMPLOYMENT
2016-present: Post Doc (University of Ferrara)
2018-present: Post Doc (Maria Cecilia Hospital, GVM Care&Research)

 

GRANTS
2016-2017: Bayer Pharma AG focus grant “Drug Discovery” ID 2016-03-1586
2019-2022: Investigator for Bando Ricerca Finalizzata 2018 (GR-2018-12367114)
2020: Investigator for CARISBO 2019 "Modulazione del PTPC come terapia per le malattie cardiovascolari di grande impatto in Emilia-Romagna"
2020: Principal Investigator "Meccanismi genetico/molecolari di autofagia nell'infezione da Covid-19” Area Science Park Trieste
2022-2024: Principal Investigator RICERCA FINALIZZATA GIOVANI RICERCATORI 2019 (GR-2019-12369862)


PROFESSIONAL SOCIETIES
2013-present: Associazione di Biologia Cellulare e del Differenziamento (ABCD)
2014: Member of the executive junior committee of Italian Society of Cell Biology and Differentiation (ABCD)
2018-present: Società Italiana di Cardiologia (SIC)

2024: Honorary Member of the European Society of Cardiology (ESC)

 

PATENTS

2018: “1,3,8-Triazaspiro derivatives and their use in therapy” (International publication number PCT/IB2019/055962)
2022: "Ureid derivatives for the treatment of reperfusion damage" (code P022397IT01)
2023: European Patent “Novel dispiropyrrolidine derivatives as mitochondrial permeability transition pore inhibitors in the treatment of reperfusion injury” (code: P023288IT-01)
NATIONAL SCIENTIFIC QUALIFICATIONS
2019: 05/H2 Histology
2020: 05/E1 General Biochemistry
AWARDS
2024: Fellow of ESC (FESC) prize.